ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

AVBP Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 45.07M shares rose 32.9% year over year, ahead of the +19.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.9% holds above the trailing-twelve-month pace of +19.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
45.07M+17.2% QoQ
Last fiscal yearDec 2025
38.46M+22.2% YoY
LTMMar 2026
40.11M+19.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.9%——
1 year+22.2%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
38.46M USD
Year-over-year change
+22.2%
4-year CAGR
+134.3%

Weighted Avg Shares (Diluted) vs competitors

How AVBP compares with its peers on the latest reported figures

  • AVBP's LTM Mar 2026 weighted avg shares (diluted) of 40.11M shares is the lowest of the 11 companies compared; the peer median is 101.7M shares.
  • Its year-over-year change of +19.2% is the 3rd highest of 11, against a peer median of +4.0%.
  • Over three fiscal years its annual growth of +4.7% compares with a peer median of +16.5%.
AVBP Competitors Peer median
Weighted Avg Shares (Diluted) for AVBP and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026353.26M +9.5%+16.4%
ERASErasca, Inc.LTM Sep 2026310.86M +9.7%+32.5%
EXELExelixis, Inc.LTM Jul 2026271.85M -6.1%-4.6%
HCMHUTCHMED (China) LimitedLTM Jun 2025174.57M +1.2%+1.0%
ZLABZai Lab LimitedLTM Jun 2026110.81M +34.8%+125.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
TYRATyra Biosciences, Inc.LTM Mar 202660.14M +2.0%+12.5%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 202657.01M +0.9%+16.7%
PBYIPuma Biotechnology, Inc.LTM Mar 202650.86M +3.4%+4.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding AVBP) 101.7M+4.0%+16.5%

Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.43M30.43M64.88M79M153.35M
Selling, General & Admin2.26M6.47M9.71M15.3M24.18M
Operating Expenses8.7M36.91M74.59M94.31M177.53M
Depreciation & Amortization036.91M000
EBITDA(51.61M)0(69.33M)(80.49M)(166.31M)
EBITDA Margin—————
Operating Income(8.7M)(36.91M)(74.59M)(94.31M)(177.53M)
Operating Margin—————
Interest Income005.26M13.82M11.23M
Interest Expense00000
Other Income / Expenses(42.91M)05.26M13.82M11.23M
Income Before Tax(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Net Margin—————
EPS (Basic)(40.44)(1.10)(2.17)(2.56)(4.32)
EPS (Diluted)(40.44)(1.10)(2.17)(2.56)(4.32)
Weighted Avg Shares1.28M33.49M31.96M31.47M38.46M
Weighted Avg Shares (Diluted)1.28M33.49M31.96M31.47M38.46M

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.